Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon
Karim Amrane, Coline Le Meur, Philippe Thuillier, Jacques Dzuko Kamga, Pierre Alemany, Frederic Chauvelot, Clémence Niel, Alex Bellange, Ronan Abgral · 2023
Read Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon by Karim Amrane, Coline Le Meur, Philippe Thuillier, Jacques Dzuko Kamga, Pierre Alemany, Frederic Chauvelot, Clémence Niel, Alex Bellange, Ronan Abgral (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10725954.txt.
Description
Melanoma of the eye is rare, aggressive, and prone to spread to the liver. Karim Amrane and co-authors report an unusual success in a 2023 case report: an eighty-one-year-old whose metastatic uveal melanoma answered to the immunotherapy drug pembrolizumab over the long term.
The catch was reading the scans. On glucose PET imaging, the tumors seemed to flare repeatedly, a pattern called pseudoprogression, where treatment-driven inflammation mimics growth. The team combined the imaging with the patient's clinical state and a blood ratio of immune cells to decide whether to persist. Their judgment to continue paid off in a dramatic, durable response. The case argues that apparent worsening on scans, in this disease and drug pairing, should not by itself end a working therapy.
Catalog record
| CREATOR | Karim Amrane, Coline Le Meur, Philippe Thuillier, Jacques Dzuko Kamga, Pierre Alemany, Frederic Chauvelot, Clémence Niel, Alex Bellange, Ronan Abgral |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |